Kabidarba comes with Preventis technology.


Darbepoetin alfa is administered subcutaneously or intravenously as a single weekly injection.

Correction of Anemia

For patients with CKD on dialysis ≥1 year of age, the initial dose by subcutaneous or intravenous administration is 0.45mcg/kg body weight, as a single injection once weekly. Alternatively, in patients not receiving dialysis, an initial dose of 0.75 mcg/kg may be administered subcutaneously or intravenously as a single injection once every 2 weeks or 1.5 mcg/kg once monthly.


Darbepoetin alfa injection is indicated for the treatment of anemia with CKD including patients on dialysis and patients not on dialysis

Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Product Information

Darbepoetin alfa is available in 25 and 40 mcg dose strengths. 25mcg/0.42 ml and 40mcg/0.40ml.

Each dose contains excipients viz., Polysorbate 80, Sodium phosphate monobasic monohydrate, Sodium phosphate dibasic anhydrous and Sodium chloride in Water for injection with pH 6.2±0.2.


1 X 25 mcg/0.42 ml single dose PFS

1 X 40 mcg/0.40 ml single dose PFS